SLC5A2 and diabetes mellitus: A systemic review and meta-analysis showed that compared to patients not taking SGLT2 inhibitors, patients without diabetes mellitus taking SGLT2 inhibitors have a statistically significant reduction in body weight, systolic blood pressure, and fasting plasma glucose [56].